CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 390	$ (548)	$ (118)
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent	(366)	(253)	(212)
Adjustments to reconcile net income (loss) from continuing operations to net cash provided by operating activities from continuing operations:
Depreciation, amortization and impairments	398	449	542
Goodwill impairment	0	54	0
Change in deferred income taxes	(342)	(27)	(60)
Stock-based compensation	113	56	32
Noncash Interest Expense	24	22	25
Inventory Write-down	7	107	15
(Gain) loss on sale of assets and other, net	22	0	(7)
Loss on debt financing transactions	0	1	100
(Gain) loss on remeasurement of debt	(41)	51	(9)
Changes in assets and liabilities, net of effects of acquisitions:
Receivables	19	137	(39)
Inventories	9	4	(21)
Other assets and liabilities	17	6	(11)
Accounts payable and accrued liabilities	98	(26)	(42)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations	304	33	209
Cash Provided by (Used in) Operating Activities, Discontinued Operations	381	438	337
Net cash provided by operating activities	685	471	546
Cash flows from investing activities:
Payments to Acquire Other Productive Assets	171	137	224
Acquisitions of businesses and assets, net of cash acquired	(186)	(13)	0
Distributions of capital from equity investments	3	0	4
Proceeds from asset sales and other	7	24	0
Net Cash Provided by (Used in) Investing Activities, Continuing Operations	(347)	(126)	(220)
Cash Provided by (Used in) Investing Activities, Discontinued Operations	(95)	(47)	(43)
Net cash used in investing activities	(442)	(173)	(263)
Cash flows from financing activities:
Borrowings under SGI revolving credit facility	60	530	270
Repayments under SGI revolving credit facility	(595)	(190)	(400)
Proceeds from issuance of notes and term loans	0	550	2,300
Payments on long-term debt	(42)	(42)	(44)
Repayments of notes and term loans (including redemption premium)	0	(341)	(2,523)
Payments of debt issuance and deferred financing costs	(5)	(10)	(35)
Payments on license obligations	(46)	(30)	(39)
Proceeds From Sale Of Finance Receivables, Financing Activities	0	0	11
Net proceeds from the sale of SciPlay common stock	0	0	342
Payments of deferred SciPlay common stock offering costs	0	0	(9)
Net redemptions of common stock under stock-based compensation plans and other	(27)	2	1
Net Cash Provided by (Used in) Financing Activities, Continuing Operations	(655)	469	(126)
Cash Provided by (Used in) Financing Activities, Discontinued Operations	(24)	(6)	(3)
Net cash (used in) provided by financing activities	(679)	463	(129)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	(6)	7	1
(Decrease) increase in cash, cash equivalents and restricted cash	(442)	768	155
Cash, cash equivalents and restricted cash, beginning of period	1,143	375	220
Cash, cash equivalents and restricted cash, end of period	701	1,143	375
Less: Cash, cash equivalents and restricted cash of discontinued operations	66	160	50
Cash, cash equivalents and restricted cash of continuing operations, end of period	635	983	325
Supplemental cash flow information:
Cash paid for interest	453	471	549
Income taxes paid	38	22	41
Payment for Contingent Consideration Liability, Operating Activities	$ 0	$ 4	$ 26